ImageneBio (NASDAQ:IMA) Stock Price Up 1.8% – What’s Next?

ImageneBio, Inc. (NASDAQ:IMA)’s stock price was up 1.8% on Tuesday . The stock traded as high as $5.74 and last traded at $5.68. 7,345 shares traded hands during trading, a decline of 26% from the average session volume of 9,902 shares. The stock had previously closed at $5.58.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImageneBio in a research note on Monday, June 29th. Wedbush reissued an “underperform” rating on shares of ImageneBio in a research note on Monday, May 11th. Finally, Wall Street Zen downgraded ImageneBio from a “sell” rating to a “strong sell” rating in a report on Sunday, May 17th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $30.00.

ImageneBio Stock Up 1.8%

The firm has a market cap of $64.47 million, a price-to-earnings ratio of -1.24 and a beta of 0.76. The firm has a 50 day moving average of $5.79 and a 200 day moving average of $5.89.

ImageneBio (NASDAQ:IMA) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.27. Equities analysts expect that ImageneBio, Inc. will post -3.07 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of IMA. Barclays PLC lifted its position in shares of ImageneBio by 170.8% during the 4th quarter. Barclays PLC now owns 10,797 shares of the company’s stock valued at $74,000 after acquiring an additional 6,810 shares during the period. Goldman Sachs Group Inc. acquired a new stake in ImageneBio in the fourth quarter worth $76,000. Millennium Management LLC acquired a new stake in ImageneBio in the fourth quarter worth $79,000. Bridgeway Capital Management LLC bought a new stake in ImageneBio in the third quarter valued at $104,000. Finally, NewEdge Advisors LLC bought a new stake in ImageneBio in the third quarter valued at $106,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.